Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy-Reference-Cited by-同舟云学术

Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy

Published:2023-02 Issue: Volume:256 Page:25-36
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Januzzi James L.^ORCID,Butler Javed,Del Prato Stefano,Ezekowitz Justin A.,Ibrahim Nasrien E.,Lam Carolyn S.P.,Lewis Gregory D.,Marwick Thomas H.,Rosenstock Julio,Tang W.H. Wilson,Zannad Faiez,Lawson Francesca,Perfetti Riccardo,Urbinati Alessia

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference66 articles.

1. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association;Pop-Busui;Diab Care,2022

2. The pathophysiological basis of diabetic cardiomyopathy development;Avagimyan;Curr Probl Cardiol,2022

3. Evidence for a specific diabetic cardiomyopathy: an observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients;Pham;Int J Endocrinol,2015

4. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes;Boonman-de Winter;Diabetologia,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions”;Acta Diabetologica;2024-09-10

2. Antidiabetic potential of fenugreek (Trigonella foenum‐graecum): A magic herb for diabetes mellitus;Food Science & Nutrition;2024-09-05

3. Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy;Cardiovascular Diabetology;2024-08-02

4. Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy;Frontiers in Endocrinology;2024-07-30

5. Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial;Heart Failure Reviews;2024-07-25